Post-gemcitabine therapy for patients with advanced pancreatic cancer - A comparative review of randomized trials evaluating oxaliplatin- and/or irinotecan-containing regimens
详细信息 查看全文
- 作者：Arndt Vogela ; vogel.arndt@mh-hannover.de" class="auth_mail" title="E-mail the corresponding author ; Fortunato Ciardiellob ; Fortunato.CIARDIELLO@unina2.it" class="auth_mail" title="E-mail the corresponding author ; Richard A. Hubnerc ; Richard.Hubner@christie.nhs.uk" class="auth_mail" title="E-mail the corresponding author ; Jean-Fré ; dé ; ric Blancd ; jean-frederic.blanc@chu-bordeaux.fr" class="auth_mail" title="E-mail the corresponding author ; Alfredo Carratoe ; acarrato@telefonica.net" class="auth_mail" title="E-mail the corresponding author ; Yoojung Yangf ; Yoojung.yang@baxalta.com" class="auth_mail" title="E-mail the corresponding author ; Dipen A. Patelg ; dpatel@pharmerit.com" class="auth_mail" title="E-mail the corresponding author ; Varun Ektareg ; vektare@pharmerit.com" class="auth_mail" title="E-mail the corresponding author ; Floris A. de Jongh ; Floris.de.Jong@shire.com" class="auth_mail" title="E-mail the corresponding author ; Sharlene Gilli ; sgill@bccancer.bc.ca" class="auth_mail" title="E-mail the corresponding author
- 关键词：Pancreatic cancer ; Oxaliplatin ; Irinotecan ; Nanoliposomal irinotecan/nal-IRI ; Randomized trial ; Indirect treatment comparison (ITC)
- 刊名：Cancer Treatment Reviews
- 出版年：2016
- 出版时间：November 2016
- 年：2016
- 卷：50
- 期：Complete
- 页码：142-147
- 全文大小：378 K
文摘
- •
Post-gemcitabine advanced pancreatic cancer patients have limited treatment options.
- •
Head-to-head comparisons of common oxaliplatin-based regimens are not available.
- •
Randomized oxaliplatin- and irinotecan-based chemotherapy trials were reviewed.
- •
Differences noted in study design, patient/treatment characteristics, and outcomes.
- •
Evaluated studies were dissimilar, precluding an indirect treatment comparison.